A new era in multiple sclerosis

Referencing Ipsos’ syndicated MS Therapy Monitor data, we explore the impact of the anti-CD20s since their availability – specifically, where they are being used, how they are being used, and neurologists’ perceptions of them.

Momentum continues to build in the use of high-efficacy, disease modifying therapies (DMTs) as a first choice for treating multiple sclerosis. How is this being influenced by the availability of anti-CD20s, a new class of DMT? Will future new therapy classes change the paradigm even further?

In a follow-up to Ipsos’ 2019 point of view, Shifting Paradigms: High-efficacy Therapies in MS Treatment, we use Ipsos’ syndicated MS Therapy Monitor data to explore the impact of the anti-CD20s since their availability – specifically, where they are being used, how they are being used, and neurologists’ perceptions of them.

We also offer a forward-looking view of the potential impact on disease progression of anti-CD20s and other new therapy classes, such as BTK inhibitors.

Download the full paper

Download

Related news

  • NASPL Possible NW
    Consumer Behavior Event

    NASPL Possible NW

    Join Ipsos as we unveil how lotteries are using mystery shopping to unlock revenue hiding in plain sight, with high-performing retailers generating significantly more revenue per square foot through specific, measurable behaviours that any retailer can replicate.
  • [WEBINAR] 2025 KEYS: The Year in Review
    Consumers Events replay

    [WEBINAR] 2025 KEYS: The Year in Review

    Join Ipsos for its complimentary KEYS webinar series dedicated to helping brands and organizations better understand the dynamics of today as they prepare for tomorrow.
  • Coffee Association of Canada Conference
    Consumers Event

    Coffee Association of Canada Conference

    We’re excited to announce that Ipsos will be speaking at the Coffee Association of Canada’s Annual Conference on November 5 at Angus Glen Golf Club!